Rituximab in severe, treatment‐refractory interstitial lung disease

Background and objective In patients with severe interstitial lung disease ( ILD ) progressing despite conventional immunosuppression, rituximab, a B ‐lymphocyte depleting monoclonal antibody, may offer an effective rescue therapy. Methods Retrospective assessment of 50 patients with severe, progressive ILD (of varying aetiologies, excluding idiopathic pulmonary fibrosis (IPF)) treated with rituximab between 2010 and 2012. Change in pulmonary...